ReviewCurrent osteoporosis reports2014
Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.
Review in Current osteoporosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- Circulating sclerostin is not suppressed following a single bout of exercise in young men.Physiological reports · 2018Trial
- The Relationship between Renin-Angiotensin-Aldosterone System (RAAS) Activity, Osteoporosis and Estrogen Deficiency in Type 2 Diabetes.International journal of molecular sciences · 2023Review
- Antitumor Effect of Sclerostin against Osteosarcoma.Cancers · 2021Article
- In silico experiments of bone remodeling explore metabolic diseases and their drug treatment.Science advances · 2020Article
- Femur Bone Mineral Density and Pentosidine Level Distinguish Ankylosing Spinal Disorder Patients with and without Sacroiliac Ankylosis.Spine surgery and related research · 2020Article
- Bone function, dysfunction and its role in diseases including critical illness.International journal of biological sciences · 2019Review
- The Bromodomain InhibitorInternational journal of molecular sciences · 2018Article
- Article
- Response of Sclerostin and Bone Turnover Markers to High Intensity Interval Exercise in Young Women: Does Impact Matter?BioMed research international · 2018Article
- Exploiting the WNT Signaling Pathway for Clinical Purposes.Current osteoporosis reports · 2017Review
- Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone.Bone reports · 2016Article
- The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives.Journal of nephrology · 2016Review
- Sclerostin Inhibition in the Management of Osteoporosis.Calcified tissue international · 2016Review
- Role of osteocytes in multiple myeloma bone disease.Current opinion in supportive and palliative care · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The SOST gene, which encodes the protein sclerostin, was identified through genetic linkage analysis of sclerosteosis and van Buchem's disease patients. Sclerostin is a secreted glycoprotein that binds to the low-density lipoprotein receptor-related proteins 4, 5, and 6 to inhibit Wnt signaling. Since the initial discovery of sclerostin, much understanding has been gained into the role of this protein in the regulation of skeletal biology. In this article, we discuss the latest findings in the regulation of SOST expression, sclerostin mechanisms of action, and the potential utility of targeting sclerostin in conditions of low bone mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.